Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

Subscribe to email list

Please select the email list(s) to which you wish to subscribe.

You are here

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

TitleNeutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
Publication TypeJournal Article
Year of Publication2012
AuthorsGoodin, DS, Hartung, H-P, O'Connor, P, Filippi, M, Arnason, B, Comi, G, Cook, S, Jeffery, D, Kappos, L, Bogumil, T, Knappertz, V, Sandbrink, R, Beckmann, K, White, R, Petkau, J, Pohl, C, Grp, BEYONDStudy
JournalMULTIPLE SCLEROSIS JOURNAL
Volume18
Pagination181-195
Date PublishedFEB
Type of ArticleArticle
ISSN1352-4585
KeywordsBEYOND study, Interferon beta-1b, multiple sclerosis, neutralizing antibodies
AbstractBackground: The frequency and impact of neutralizing antibodies (NAbs) to interferon beta-1b (IFN beta-1b) on clinical and radiographic outcomes is controversial. Objective: To assess NAb impact in the BEYOND study. Methods: 2244 patients were randomized (2:2:1) to receive IFN beta-1b, either 250 or 500 mu g, or glatiramer acetate, 20 mg, and observed for 2-3.5 years. NAb titers were determined every 6 months. A titer >= 20 NU/ml was considered NAb positive. Efficacy was compared between NAb-positive and NAb-negative patients, using comprehensive statistical analyses, taking into account the delayed appearance of NAbs, the time-dependent changes in the relapse rate, spontaneous reversions to NAb-negative status, NAb-titer level, and also adjusting for baseline factors. Results: In the IFN beta-1b 250 mu g group, NAb-positive titers were detected (>= once) in 319 patients (37.0%); of these, 112 (35.1%) reverted to NAb-negative status. In the IFN beta-1b 500 mu g group, 340 patients (40.7%) became NAb-positive and 119 (35.0%) reverted to NAb-negative status. In both IFN beta groups, especially the 250 mu g arm, NAb-positive status was not associated with a convincing impact on any clinical outcome measure by any statistical analysis. By contrast, in both IFN beta groups, NAbs were associated with a very consistent deleterious impact on most MRI outcomes. Conclusion: There was a notable dissociation between the impact of NAbs on MRI and clinical outcomes. On MRI measures, the impact was consistent and convincing, whereas on clinical measures a negative impact of NAbs was not found. The basis for this clinico-radiographic paradox is unknown but it suggests that the relationship between NAbs and the therapeutic effects of IFN beta-1b is complex.
DOI10.1177/1352458511418629